WebMay 2, 2024 · BIIB078 for the Treatment of C9orf72-Related ALS. Individuals diagnosed with C9orf72-related ALS are being recruited by selected sites for the first-in-human … WebMar 29, 2024 · Biogen's new drug, BIIB078, was an antisense oligonucleotide meant to treat ALS patients with a specific genetic mutation, or the C9orf72 gene. Antisense is a drug technology used to build ...
Biogen : Phase 1 Study Of BIIB078 On Amyotrophic Lateral
WebMar 29, 2024 · Mar 29, 2024 01:03PM EDT. Biogen BIIB and partner Ionis Pharmaceuticals IONS announced disappointing top-line results from a phase I study evaluating their investigational antisense drug, BIIB078 ... WebDec 19, 2024 · Biogen’s Spinraza for spinal muscular atrophy (SMA) came out of their partnership. The two companies are also working to develop BIIB067 (tofersen) for amyotrophic lateral sclerosis (ALS), which Biogen licensed from Ionis in 2024, as well as IONIS-C9Rx (BIIB078) for ALS, and ION859, for Parkinson’s disease. dany origine
Biogen R&D Day to Provide Overview of Diversified Pipeline and
WebMar 28, 2024 · Biogen (BIIB) and Ionis Pharmaceuticals (IONS) announced on Monday that the companies would terminate the clinical development of BIIB078, a candidate for C9orf72-associated... WebOct 9, 2024 · Ionis Pharmaceuticals announced the first person with ALS was given their experimental antisense oligonucleotide (ASO) treatment, known as BIIB078, specifically targeting C9orf72 in a phase 1 clinical trial being executed by their development partner, Biogen. According to the partners, 34% of familial ALS cases are related to C9orf72, … WebMar 28, 2024 · This press release includes forward-looking statements regarding Ionis' business, and the therapeutic and commercial potential of Ionis' technologies, IONIS-C9 Rx (BIIB078) and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking … birthe arnbak